Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Invasive diagnosis of pulmonary hypertension and its effects on the right heart].

Deutsche medizinische Wochenschrift (1946)·2006

Same author

[Subclinical albuminuria, microalbuminuria and proteinuria--accepted cardiovascular risk markers?].

Deutsche medizinische Wochenschrift (1946)·2006

Same author

Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.

British journal of cancer·2006

Same author

Non-pigmentary actions of alpha-melanocyte-stimulating hormone--lessons from the cutaneous melanocortin system.

Cellular and molecular biology (Noisy-le-Grand, France)·2006

Same author

Soliton-radiation beat analysis.

Physical review. E, Statistical, nonlinear, and soft matter physics·2006

Same author

[Radionuclide bone scan in patients with newly diagnosed prostate cancer. Clinical aspects and cost analysis].

Der Urologe. Ausg. A·2006

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

[Update on anti-platelet therapy].

S H Schirmer¹, M Böhm

¹Kardiologie, Angiologie und Internistische Intensivmedizin, Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar. Stephan.Schirmer@uks.eu

Deutsche Medizinische Wochenschrift (1946)

|June 2, 2011

Summary

This summary is machine-generated.

New antiplatelet drugs like prasugrel and ticagrelor offer improved efficacy over clopidogrel for acute coronary syndromes. Ticagrelor shows promise in reducing ischemic events and total mortality without increasing major bleeding.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Experiment Videos

Last Updated: Jun 1, 2026

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Area of Science:

Cardiology
Pharmacology
Thrombosis

Background:

Clopidogrel, an ADP (P2Y12)-receptor antagonist, is standard for dual platelet inhibition in acute coronary syndromes and after stent placement.
Clopidogrel's efficacy can be limited by its metabolism into an active form and irreversible receptor inhibition, especially in poor responders.
Novel antiplatelet agents are emerging to address clopidogrel's limitations.

Purpose of the Study:

To review current data on novel antiplatelet inhibitors.
To delineate the potential clinical impact of new drugs compared to clopidogrel.
To discuss the influence of these agents on managing acute coronary syndromes.

Main Methods:

Review of clinical trial data (TRITON-TIMI-38 for prasugrel, PLATO for ticagrelor).
Comparison of efficacy and safety profiles of novel agents versus clopidogrel.
Analysis of platelet inhibition, ischemic events, bleeding complications, and mortality.

Main Results:

Prasugrel demonstrated stronger platelet inhibition and fewer ischemic events than clopidogrel, but with increased bleeding.
Ticagrelor, a direct-acting antagonist, showed superiority over clopidogrel in reducing platelet aggregation and ischemic events.
Ticagrelor did not increase major bleeding and was associated with reduced total mortality.

Conclusions:

Novel ADP-receptor antagonists, prasugrel and ticagrelor, offer advantages over clopidogrel in specific clinical scenarios.
Ticagrelor presents a favorable profile with reduced ischemic events and mortality, without a significant bleeding increase.
These agents are poised to influence clinical practice in managing acute coronary syndromes and post-stent implantation.